Skip to main content
. 2021 Apr 8;6(7):e141912. doi: 10.1172/jci.insight.141912

Figure 4. PRGN-2009 treatment resulted in decreased tumor volumes and increased intratumoral immune cell effector subsets.

Figure 4

C57BL/6 mice (n = 7–8 per group) bearing s.c. TC-1 HPV16+ murine tumors were treated in 2 separate studies with empty vector control (1 × 109 VP, s.c.), PBS (100 μL, s.c.), or PRGN-2009 (1 × 109 VP, s.c.) on days 7 and 14 after tumor implantation. (A) Study 1, end-of-study tumor weights for individual mice. (B) Study 2, end-of-study tumor weights for individual mice. (C) Meta-analysis of both studies, showing end-of-study tumor weights. (D–F) Flow cytometry of single-cell suspensions of tumor tissue. T cell subsets are shown per mg tumor. The Ki67 stain was only performed in 1 study. Figures show the medians. Mann-Whitney U and Kruskal-Wallis tests were used. *P < 0.05, **P < 0.01, ***P < 0.001. VP, virus particles.